KIT and gastrointestinal stromal tumor: In our previous work, we demonstrated that secondary KIT mutations were observed only in GIST-T1 cells subjected to long-term imatinib exposure, but not in cells exposed for a short duration [22], supporting the idea that early-phase resistance is mediated by non-genetic adaptations.